Results 11 to 20 of about 25,648 (169)

Constitutive IP₃ signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP₃ receptor disruptor BIRD-2 [PDF]

, 2018
Anti-apoptotic Bcl-2 proteins are upregulated in different cancers, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), enabling survival by inhibiting pro-apoptotic Bcl-2-family members and inositol 1,4,5 ...
Akl, Haidar, Baes, Myriam, Bittremieux, Mart, Bootman, Martin D., Bultynck, Geert, De Smedt, Humbert, Dubron, Kathia, Efremov, Dimitar G., Janssens, Ann, La Rovere, Rita M., Laurenti, Luca, Martines, Claudio, Mikoshiba, Katsuhiko, Morciano, Giampaolo, Parys, Jan B., Pinton, Paolo, Rietdorf, Katja, Vandenberghe, Peter, Welkenhuyzen, Kirsten   +18 more
core   +3 more sources

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia

Journal of Hematology & Oncology, 2022
Inhibitors of B cell receptor (BCR) signaling such as the Bruton’s tyrosine kinase (BTK) inhibitors are effective therapeutics for chronic lymphocytic leukemia (CLL).
Elizabeth M. Muhowski, Janani Ravikrishnan, Britten Gordon, Lianbo Yu, Shrilekha Misra, Brandi Walker, Sudharshan Eathiraj, Deepa Sampath, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach   +10 more
doaj   +1 more source

Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia

Haematologica, 2023
CD40 signaling upregulates BCL-XL and MCL-1 expression in the chronic lymphocytic leukemia (CLL) lymph node microenvironment, affording resistance to the BCL-2 inhibitor, venetoclax.
Zhenghao Chen, Gaspard Cretenet, Valeria Carnazzo, Helga Simon-Molas, Arnon P. Kater, Gerritje J. W. van der Windt, Eric Eldering   +6 more
doaj   +1 more source

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? [PDF]

, 2017
INTRODUCTION: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder.
Ansuinelli, Michela, DE ANGELIS, Federico, DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio   +4 more
core   +1 more source

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies

Cancer Cell International, 2020
Venetoclax has been approved by the United States Food and Drug Administration since 2016 as a monotherapy for treating patients with relapsed/refractory chronic lymphocytic leukemia having 17p deletion.
XiaoYan Yue, Qingxiao Chen, JingSong He
doaj   +1 more source

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT [PDF]

, 2017
Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation ...
Beelen, Dietrich, Bittenbring, Jörg, Blaise, Didier, Blok, Henric-Jan, Castagna, Luca, Chevallier, Patrice, Ciceri, Fabio, Corradini, Paolo, Eikema, Dirk-Jan, Foá, Roberto, Hallek, Michael, Hilgendorf, Inken, Koc, Yener, Kröger, Nicolaus, Moreno, Carol, Müller, Lutz Peter, Schetelig, Johannes, Selleslag, Dominik, Solano, Carlos, Theobald, Matthias, Tischer, Johanna, van Gelder, Michel, van Gorkom, Gwendolyn, van Lint, M. T.   +23 more
core   +1 more source

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis

Cell Death and Disease, 2022
Venetoclax plus cytarabine therapy is approved for elderly acute myeloid leukemia (AML) patients and needs further improvement. We studied the mechanisms of venetoclax plus cytarabine treatment and searched for a third agent to enhance their effects ...
Jingyi Zhang, Yuetong Wang, Chujie Yin, Ping Gong, Zhenwei Zhang, Linxiang Zhao, Samuel Waxman, Yongkui Jing   +7 more
doaj   +1 more source

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia

Haematologica, 2022
The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particularly ...
Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta, Amanda Ranta, Jani Huuhtanen, Minna Suvela, Alun Parsons, Annasofia Holopainen, Anu Partanen, Milla E.L. Kuusisto, Sirpa Koskela, Riikka Räty, Maija Itälä-Remes, Imre Västrik, Olli Dufva, Sanna Siitonen, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Mika Kontro   +24 more
doaj   +1 more source

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)

Pathology and Oncology Research, 2023
Introduction: The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation.
Andrea Ceglédi, Zoltán Csukly, Mónika Fekete, András Kozma, Zsuzsanna Szemlaky, Hajnalka Andrikovics, Gábor Mikala   +6 more
doaj   +1 more source

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. [PDF]

, 2018
The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes.
Aftab, Blake T, Ferguson, Ian D, Hann, Byron C, Lam, Christine, Lin, Yu-Hsiu T, Liu, Hui, Liu, Jun O, Mariano, Margarette C, Mitsiades, Constantine S, Murnane, Megan, Smith, Geoffrey A, Taunton, Jack, Wiita, Arun P, Wong, Sandy W   +13 more
core   +2 more sources